-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Venezuelan -X- _ O
equine -X- _ O
encephalitis -X- _ O
virus -X- _ O
( -X- _ O
VEEV -X- _ O
) -X- _ O
is -X- _ O
responsible -X- _ O
for -X- _ O
VEE -X- _ O
epidemics -X- _ O
that -X- _ O
occur -X- _ O
in -X- _ O
South -X- _ O
and -X- _ O
Central -X- _ O
America -X- _ O
and -X- _ O
the -X- _ O
U.S. -X- _ O
The -X- _ O
VEEV -X- _ O
envelope -X- _ O
contains -X- _ O
two -X- _ O
glycoproteins -X- _ O
E1 -X- _ O
( -X- _ O
mediates -X- _ O
cell -X- _ O
membrane -X- _ O
fusion -X- _ O
) -X- _ O
and -X- _ O
E2 -X- _ O
( -X- _ O
binds -X- _ O
receptor -X- _ O
and -X- _ O
elicits -X- _ O
virus -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
) -X- _ O
. -X- _ O
Previously -X- _ O
we -X- _ O
constructed -X- _ O
E1 -X- _ O
and -X- _ O
E2 -X- _ O
epitope -X- _ O
maps -X- _ O
using -X- _ O
murine -X- _ O
monoclonal -X- _ O
antibodies -X- _ O
( -X- _ O
mMAbs -X- _ O
) -X- _ O
. -X- _ O
Six -X- _ O
E2 -X- _ O
epitopes -X- _ O
( -X- _ O
E2 -X- _ O
( -X- _ O
c -X- _ O
, -X- _ O
d -X- _ O
, -X- _ O
e -X- _ O
, -X- _ O
f -X- _ O
, -X- _ O
g -X- _ O
, -X- _ O
h -X- _ O
) -X- _ O
) -X- _ O
bound -X- _ O
VEEV-neutralizing -X- _ O
antibody -X- _ O
and -X- _ O
mapped -X- _ O
to -X- _ O
amino -X- _ O
acids -X- _ O
( -X- _ O
aa -X- _ O
) -X- _ O
182–207. -X- _ O
Nothing -X- _ O
is -X- _ O
known -X- _ O
about -X- _ O
the -X- _ O
human -X- _ O
antibody -X- _ O
repertoire -X- _ O
to -X- _ O
VEEV -X- _ O
or -X- _ O
epitopes -X- _ O
that -X- _ O
engage -X- _ O
human -X- _ O
virus-neutralizing -X- _ O
antibodies. -X- _ O
There -X- _ O
is -X- _ O
no -X- _ O
specific -X- _ O
treatment -X- _ O
for -X- _ O
VEE -X- _ O
; -X- _ O
however -X- _ O
virus-neutralizing -X- _ B-Intervention
mMAbs -X- _ I-Intervention
are -X- _ O
potent -X- _ O
protective -X- _ O
and -X- _ O
therapeutic -X- _ O
agents -X- _ O
for -X- _ O
mice -X- _ B-Patient
challenged -X- _ I-Patient
with -X- _ I-Patient
VEEV -X- _ I-Patient
by -X- _ I-Patient
either -X- _ I-Patient
peripheral -X- _ I-Patient
or -X- _ I-Patient
aerosol -X- _ I-Patient
routes. -X- _ I-Patient
Therefore -X- _ O
, -X- _ O
fully -X- _ O
human -X- _ B-Intervention
MAbs -X- _ I-Intervention
( -X- _ I-Intervention
hMAbs -X- _ I-Intervention
) -X- _ I-Intervention
with -X- _ O
virus-neutralizing -X- _ O
activity -X- _ O
should -X- _ O
be -X- _ O
useful -X- _ O
for -X- _ O
prevention -X- _ O
or -X- _ O
clinical -X- _ O
treatment -X- _ O
of -X- _ O
human -X- _ O
VEE. -X- _ O
METHODS -X- _ O
: -X- _ O
We -X- _ O
used -X- _ O
phage-display -X- _ O
to -X- _ O
isolate -X- _ O
VEEV-specific -X- _ B-Intervention
hFabs -X- _ I-Intervention
from -X- _ O
human -X- _ O
bone -X- _ O
marrow -X- _ O
donors. -X- _ O
These -X- _ O
hFabs -X- _ O
were -X- _ O
characterized -X- _ O
by -X- _ O
sequencing -X- _ O
, -X- _ O
specificity -X- _ O
testing -X- _ O
, -X- _ O
VEEV -X- _ O
subtype -X- _ O
cross-reactivity -X- _ O
using -X- _ O
indirect -X- _ O
ELISA -X- _ O
, -X- _ O
and -X- _ O
in -X- _ O
vitro -X- _ O
virus -X- _ O
neutralization -X- _ O
capacity. -X- _ O
One -X- _ O
E2-specific -X- _ O
neutralizing -X- _ O
hFAb -X- _ O
, -X- _ O
F5n -X- _ O
, -X- _ O
was -X- _ O
converted -X- _ O
into -X- _ O
IgG -X- _ O
, -X- _ O
and -X- _ O
its -X- _ O
binding -X- _ O
site -X- _ O
was -X- _ O
identified -X- _ O
using -X- _ O
competitive -X- _ O
ELISA -X- _ O
with -X- _ O
mMAbs -X- _ B-Intervention
and -X- _ O
by -X- _ O
preparing -X- _ O
and -X- _ O
sequencing -X- _ O
antibody -X- _ O
neutralization-escape -X- _ O
variants. -X- _ O
FINDINGS -X- _ O
: -X- _ O
Using -X- _ B-Outcome
11 -X- _ I-Outcome
VEEV-reactive -X- _ I-Outcome
hFabs -X- _ I-Outcome
we -X- _ I-Outcome
constructed -X- _ I-Outcome
the -X- _ I-Outcome
first -X- _ I-Outcome
human -X- _ I-Outcome
epitope -X- _ I-Outcome
map -X- _ I-Outcome
for -X- _ I-Outcome
the -X- _ I-Outcome
alphaviral -X- _ I-Outcome
surface -X- _ I-Outcome
proteins -X- _ I-Outcome
E1 -X- _ I-Outcome
and -X- _ I-Outcome
E2. -X- _ I-Outcome
We -X- _ I-Outcome
identified -X- _ I-Outcome
an -X- _ I-Outcome
important -X- _ I-Outcome
neutralization-associated -X- _ I-Outcome
epitope -X- _ I-Outcome
unique -X- _ I-Outcome
to -X- _ I-Outcome
the -X- _ I-Outcome
human -X- _ I-Outcome
immune -X- _ I-Outcome
response -X- _ I-Outcome
, -X- _ I-Outcome
E2 -X- _ I-Outcome
aa115–119. -X- _ I-Outcome
Using -X- _ I-Outcome
a -X- _ I-Outcome
9 -X- _ I-Outcome
Å -X- _ I-Outcome
resolution -X- _ I-Outcome
cryo-electron -X- _ I-Outcome
microscopy -X- _ I-Outcome
map -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
Sindbis -X- _ I-Outcome
virus -X- _ I-Outcome
E2 -X- _ I-Outcome
protein -X- _ I-Outcome
, -X- _ I-Outcome
we -X- _ I-Outcome
showed -X- _ I-Outcome
the -X- _ I-Outcome
probable -X- _ I-Outcome
surface -X- _ I-Outcome
location -X- _ I-Outcome
of -X- _ I-Outcome
this -X- _ I-Outcome
human -X- _ I-Outcome
VEEV -X- _ I-Outcome
epitope. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
The -X- _ O
VEEV-neutralizing -X- _ B-Intervention
capacity -X- _ I-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
hMAb -X- _ I-Intervention
F5 -X- _ I-Intervention
nIgG -X- _ I-Intervention
is -X- _ O
similar -X- _ B-Outcome
to -X- _ I-Outcome
that -X- _ I-Outcome
exhibited -X- _ I-Outcome
by -X- _ I-Outcome
the -X- _ I-Outcome
humanized -X- _ I-Outcome
mMAb -X- _ I-Outcome
Hy4 -X- _ I-Outcome
IgG. -X- _ I-Outcome
The -X- _ I-Outcome
Hy4 -X- _ I-Outcome
IgG -X- _ I-Outcome
has -X- _ I-Outcome
been -X- _ I-Outcome
shown -X- _ I-Outcome
to -X- _ I-Outcome
limit -X- _ I-Outcome
VEEV -X- _ I-Outcome
infection -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
both -X- _ I-Outcome
prophylactically -X- _ I-Outcome
and -X- _ I-Outcome
therapeutically. -X- _ I-Outcome
Administration -X- _ I-Outcome
of -X- _ I-Outcome
a -X- _ I-Outcome
cocktail -X- _ I-Outcome
of -X- _ I-Outcome
F5n -X- _ I-Outcome
and -X- _ I-Outcome
Hy4 -X- _ I-Outcome
IgGs -X- _ I-Outcome
, -X- _ I-Outcome
which -X- _ I-Outcome
bind -X- _ I-Outcome
to -X- _ I-Outcome
different -X- _ I-Outcome
E2 -X- _ I-Outcome
epitopes -X- _ I-Outcome
, -X- _ I-Outcome
could -X- _ I-Outcome
provide -X- _ I-Outcome
enhanced -X- _ I-Outcome
prophylaxis -X- _ I-Outcome
or -X- _ I-Outcome
immunotherapy -X- _ I-Outcome
for -X- _ I-Outcome
VEEV -X- _ I-Outcome
, -X- _ I-Outcome
while -X- _ I-Outcome
reducing -X- _ I-Outcome
the -X- _ I-Outcome
possibility -X- _ I-Outcome
of -X- _ I-Outcome
generating -X- _ I-Outcome
possibly -X- _ I-Outcome
harmful -X- _ I-Outcome
virus -X- _ I-Outcome
neutralization-escape -X- _ I-Outcome
variants -X- _ I-Outcome
in -X- _ I-Outcome
vivo -X- _ I-Outcome
. -X- _ O

